Chenomx, Inc Announces Metabolite Database for ACD/Labs
The Chenomx Metabolite Database for ACD/Labs contains 800MHz 1H NMR spectra for 265 of the most commonly found metabolites in urine and blood. This database enables metabolomics researchers to easily identify a peak of interest in an NMR spectrum by searching against potential matches in the Chenomx Metabolite Database. By making use of Chenomx’s world-class reference database of NMR spectra, ACD/Labs’ metabolomics users will be able to perform routine peak identification directly from within ACD/1D NMR Manager. This is in addition to the current capabilities of phase correction, baseline correction, and Intelligent Bucketing (or Binning) for batches of spectra. Now, users can employ the ACD/Labs software to take them much further by utilizing the Chenomx Metabolite database to help them identify some of the components of their biofluid samples.
Brent Lefebvre, NMR Product Manager for ACD/Labs, comments on the new Chenomx Metabolite Database for ACD/Labs, “The decision to partner with Chenomx to supply the metabolite spectra for this database was an easy one. Chenomx is the leader in metabolic profiling by NMR and could provide our users with the best possible spectral database. Now, users will be able to spot a peak that is of interest to them in a biofluid spectrum, and easily search the database of common metabolites for it. If the metabolite is one that is commonly occuring, they will have just saved themselves an enormous amount of work searching disparate locations for this information.”
Jack Newton, Director of Product Development for Chenomx, says, “Both Chenomx and ACD/Labs offer sophisticated software solutions to the rapidly growing NMR metabolomics community. Chenomx is happy to partner with ACD/Labs to provide this database to users that are looking to answer basic questions about what compounds are present in their NMR spectra. Although Chenomx offers a rich set of tools for performing targeted metabolite identification and quantitation, not all users require this level of sophistication. To address the needs of all of our users, we are proud to present this joint ACD/Labs-Chenomx solution.”
The database will be unveiled on Wednesday, December 7th, 2005 at the CHI Conference on Metabolic Profiling in Buena Vista, Florida, USA.
About Advanced Chemistry Development, Inc.
Advanced Chemistry Development, Inc., (ACD/Labs) is a chemistry software company offering solutions that truly integrate chemical structures with analytical chemistry information to produce ChemAnalytics®. ACD/Labs creates innovative software packages that aid chemical research scientists worldwide with spectroscopic validation of structures, elucidation of unknown substances, chromatographic separation, medicinal chemistry, preformulation of novel drug agents, systematic nomenclature generation, and chemical patenting and publication. Combined, ACD/Labs’ solutions create an analytical informatics system that provides dramatic feed-forward effects on the chemical and pharmaceutical research process. Founded in 1993, and headquartered in Toronto, Canada, ACD/Labs employs a team of over 100 dedicated individuals whose continual efforts carry ACD/Labs’ innovative technologies into pharmaceutical, biotech, chemical, and materials companies throughout the world. Information about Advanced Chemistry Development and its products is available at www.acdlabs.com .
About Chenomx, Inc.
Chenomx, Inc. is a privately-held Canadian company that specializes in the development of complex mixture analysis software for broad application in life science technologies. With world-class expertise in NMR spectroscopy, pharmaceutical sciences, and computer software, Chenomx offers a broad range of software products and compound databases to support the metabolomics communities’ research efforts. Chenomx’s flagship product, Chenomx NMR Suite, provides a rich set of tools for indentifying and quantifying metabolites in complex NMR Spectra. More information on Chenomx and its solutions is available at www.chenomx.com .
